ANGLE plc provided earnings guidance for the year 2023. The Company expects revenue recognised for 2023 will be c. £2.2 million, which is an increase of 120% over revenue achieved in 2022 but below current market consensus of c. £3.0 million. New sales secured in 2023 are expected to be c. £3.3 million however revenue recognition for some of these sales will fall into the 2024 financial year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21 GBX | 0.00% | +18.31% | +78.72% |
05-03 | Angle shares up on assay development deal with AstraZeneca | AN |
05-03 | Angle shares up on assay development deal with AstraZenaca | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+78.72% | 68.45M | |
-42.86% | 2.85B | |
+20.51% | 1.94B | |
-1.13% | 1.68B | |
+27.00% | 1.26B | |
-14.07% | 1.03B | |
-20.60% | 938M | |
+0.88% | 783M | |
-24.34% | 628M | |
+8.73% | 535M |
- Stock Market
- Equities
- AGL Stock
- News ANGLE plc
- ANGLE plc Provides Earnings Guidance for the Year 2023